Clinical Outcomes of Myocarditis after Moderate-Dose Steroid Therapy in Systemic Sclerosis: A Pilot Study.
Journal
International journal of rheumatology
ISSN: 1687-9260
Titre abrégé: Int J Rheumatol
Pays: United States
ID NLM: 101519204
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
09
2020
revised:
26
11
2020
accepted:
08
12
2020
entrez:
8
1
2021
pubmed:
9
1
2021
medline:
9
1
2021
Statut:
epublish
Résumé
Myocarditis is reported in systemic sclerosis (SSc); however, treatment options and outcomes are limited. Our objective was to define cardiac outcomes after moderate-dose steroid therapy in SSc patients with myocarditis. An open-label study was conducted among SSc patients with myocarditis-as defined by cardiovascular magnetic resonance (CMR), disease onset <5 years, and a NYHA functional class ≥II. All enrolled patients received prednisolone (30 mg/d) which would be tapered off by week 24, and CMR was followed up at the end of treatment. A total of 20 SSc patients were enrolled which 12 patients completed the study. At week 24, 8 of the 12 cases experienced improvement of myocarditis. Compared to those with no improvement, these 8 patients had significantly longer disease duration ( Moderate-dose steroid therapy may improve myocarditis in SSc. A proportion of patients died due to cardiac complications during treatment, particularly those with high hs-cTnT, high NT-proBNP, and impaired LVEF. This trial is registered with NCT03607071.
Sections du résumé
BACKGROUND
BACKGROUND
Myocarditis is reported in systemic sclerosis (SSc); however, treatment options and outcomes are limited. Our objective was to define cardiac outcomes after moderate-dose steroid therapy in SSc patients with myocarditis.
METHOD
METHODS
An open-label study was conducted among SSc patients with myocarditis-as defined by cardiovascular magnetic resonance (CMR), disease onset <5 years, and a NYHA functional class ≥II. All enrolled patients received prednisolone (30 mg/d) which would be tapered off by week 24, and CMR was followed up at the end of treatment.
RESULTS
RESULTS
A total of 20 SSc patients were enrolled which 12 patients completed the study. At week 24, 8 of the 12 cases experienced improvement of myocarditis. Compared to those with no improvement, these 8 patients had significantly longer disease duration (
CONCLUSIONS
CONCLUSIONS
Moderate-dose steroid therapy may improve myocarditis in SSc. A proportion of patients died due to cardiac complications during treatment, particularly those with high hs-cTnT, high NT-proBNP, and impaired LVEF. This trial is registered with NCT03607071.
Identifiants
pubmed: 33414828
doi: 10.1155/2020/8884442
pmc: PMC7769651
doi:
Banques de données
ClinicalTrials.gov
['NCT03607071']
Types de publication
Journal Article
Langues
eng
Pagination
8884442Informations de copyright
Copyright © 2020 Burabha Pussadhamma et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflict of interests.
Références
J Rheumatol. 1985 Oct;12(5):997-9
pubmed: 4087278
Rheumatology (Oxford). 2000 Jun;39(6):674-9
pubmed: 10888714
Semin Arthritis Rheum. 2017 Aug;47(1):79-85
pubmed: 28522072
Semin Arthritis Rheum. 2014 Feb;43(4):526-35
pubmed: 23932313
Curr Opin Rheumatol. 2011 Nov;23(6):545-54
pubmed: 21897256
Rheumatology (Oxford). 2017 Jun 1;56(6):912-921
pubmed: 28160468
World J Cardiol. 2014 Sep 26;6(9):993-1005
pubmed: 25276300
J Am Coll Cardiol. 2013 Oct 1;62(14):1252-1259
pubmed: 23623916
Arthritis Rheum. 1998 Sep;41(9):1613-9
pubmed: 9751093
Clin Cardiol. 1993 Dec;16(12):895-9
pubmed: 8168276
BMC Cardiovasc Disord. 2017 Jul 17;17(1):187
pubmed: 28716007
Ann Rheum Dis. 2007 Jul;66(7):940-4
pubmed: 17329309
Am Fam Physician. 2003 Aug 1;68(3):483-8
pubmed: 12924831
Eur Heart J. 2017 Sep 14;38(35):2649-2662
pubmed: 28655210
Eur J Heart Fail. 2008 Sep;10(9):824-39
pubmed: 18760965
J Rheumatol. 1988 Feb;15(2):202-5
pubmed: 3361530
Ann Rheum Dis. 2010 Oct;69(10):1809-15
pubmed: 20551155
Arthritis Rheum. 1996 Apr;39(4):677-81
pubmed: 8630120
Eur Respir J. 2019 Jan 24;53(1):
pubmed: 30545968
Eur J Heart Fail. 2010 Mar;12(3):268-75
pubmed: 20071354
Ann Rheum Dis. 2005 Sep;64(9):1268-73
pubmed: 15708883
Scand J Rheumatol. 2010 Aug;39(4):349-50
pubmed: 20476869
Ann Intern Med. 1986 Nov;105(5):661-8
pubmed: 3767147
Arthritis Rheum. 1991 Feb;34(2):198-203
pubmed: 1994918
Medicine (Baltimore). 2002 Mar;81(2):139-53
pubmed: 11889413
Arthritis Rheum. 1981 May;24(5):662-8
pubmed: 7236323
Am J Med. 2012 May;125(5):491-498.e1
pubmed: 22482847
J Rheumatol. 2009 Jan;36(1):106-12
pubmed: 19040307
Circulation. 1974 Oct;50(4):844-56
pubmed: 4425013
N Engl J Med. 1986 May 29;314(22):1397-402
pubmed: 3486363
Chest. 1992 Mar;101(3):872-4
pubmed: 1541169
Semin Arthritis Rheum. 1989 Dec;19(3):191-200
pubmed: 2690346
Int J Cardiol. 2016 Aug 15;217:135-48
pubmed: 27179903
Semin Hematol. 2015 Oct;52(4):261-9
pubmed: 26404438
Ann Rheum Dis. 2013 Nov;72(11):1747-55
pubmed: 24092682
J Cardiovasc Magn Reson. 2014 Mar 04;16:21
pubmed: 24593856
Clin Exp Rheumatol. 2001 Jul-Aug;19(4):431-7
pubmed: 11491499